Business
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development
HONG KONG, HK / ACCESS Newswire / March 10, 2026 / CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences" or the "Company", Stock Code: 0775) today announced the establishment of Sequencio Therapeutics ("Sequencio"), a wholly-owned subsidiary ...
About this update from Dogwood Therapeutics, Inc.
[{"type":"text","content":"HONG KONG, HK / ACCESS Newswire / March 10, 2026 / CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences" or the "Company", Stock Code: 0775) today announced the establishment of Sequencio Therapeutics ("Sequencio"), a wholly-owned subsidiary dedicated to advancing the Company's therapeutic cancer vaccine portfolio.","length":361,"tagName":"p"},{"type":"text","content":"The Third Pillar of a Strategic Reorganisation","length":46,"tagName":"p"},{"type":"text","content":"This marks the third pillar of a strategic reorganisation, following transactions involving Nasdaq-listed TransCode Therapeutics ("TransCode", "RNAZ") and Dogwood Therapeutics ("Dogwood", "DWTX") completed in 2025 and 2024, respectively. Collectively, these developments are intended to accelerate R&D, enhance operational execution, and broaden capital access for pharmaceuticals and diagnostics R&D, positioning CK Life Sciences at the forefront of therapeutic cancer vaccine development.","length":538,"tagName":"p"},{"type":"text","content":"Sequencio - A Therapeutic Cancer Vaccine R&D Platform","length":57,"tagName":"p"},{"type":"text","content":"Sequencio Therapeutics has been established to consolidate CK Life Sciences' therapeutic cancer vaccine research and development portfolio under a dedicated organisation, reflecting the Company's strategic focus on this emerging class of cancer immunotherapy. The subsidiary is focused on the development of therapeutic cancer vaccines designed to train a patient's own immune system to achieve durable, long-term remission with a favourable safety profile, addressing key limitations of current standard-of-care therapies. The establishment of Sequencio supports a long-term vision of shifting cancer treatment paradigms from transient tumour reduction toward sustained, immune-controlled remission, with vaccine discovery and design conducted in-house and development advanced through a combination of internal capabilities and external collaborations.","length":866,"tagName":"p"},{"type":"text","content":"Sequencio's preclinical portfolio includes the Company's investigational cancer vaccines targeting Trophoblast Cell Surface Antigen 2 (TROP2), which has demonstrated robust T-cell immune responses and achieved 100% t...